LONDON/COPENHAGEN, Oct 7 (Reuters) – Wegovy-maker Novo Nordisk has laid off dozens of employees at the largest U.S. manufacturing site for its blockbuster obesity and diabetes drugs, a Reuters review of LinkedIn posts showed, a signal of where it is making cuts in a major restructuring under new CEO Mike Doustdar.
The previously unreported cuts included staff in manufacturing roles, from quality control to production line technicians, at Novo’s major Clayton, North Carolina, plant and other facilities in the state, an analysis of 73 posts and profiles show.
Sign up here.
The Danish drugmaker last year became Europe’s most valuable listed company on unprecedented demand for weight-loss drugs before a sharp share price slide as sales growth slowed. It is now trying to turn around its fortunes and reduce costs and staff that bloated as it rode the Wegovy boom.
A Novo spokesperson declined a Reuters request for further details beyond last month’s global layoffs announcement.
Exclusive: Novo Nordisk cuts hit production line jobs at key US plant, posts show
